Jesse Wayne Hall - 01 May 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 May 2025
Net transactions value
$0
Form type
4
Filing time
05 May 2025, 16:32:56 UTC
Next filing
06 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hall Jesse Wayne Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE /s/ Matthew Rothman, Attorney-in-Fact 05 May 2025 0002065269

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Award $0 +145,500 $0.000000 145,500 01 May 2025 Common Stock 145,500 Direct F1, F2
transaction ACRS Employee Stock Option (right to buy) Award $0 +510,000 $0.000000 510,000 01 May 2025 Common Stock 510,000 $1.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.